Presentations

Date	Title	Documents
08/07/23	PLX Corporate Presentation (August 2023)	PLX Corporate Presentation (August 2023) 538.4 KB
02/24/23	“Long-term Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: 2-year Interim Results from the Ongoing Phase 3 BRIGHT51 Open-label Extension Study”	“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Presentation By Eric L. Wallace, M.D., at the 19th Annual WorldSymposium 2023 1.3 MB
02/24/23	“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Presentation By Eric L. Wallace, M.D., at the 19th Annual WorldSymposium 2023	“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Presentation By Eric L. Wallace, M.D., at the 19th Annual WorldSymposium 2023 926 KB
02/22/23	“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Poster Presentation By Eric L. Wallace, M.D.	“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Poster Presentation By Eric L. Wallace, M.D. 1.2 MB
02/22/23	“Long-term Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: 2-year Interim Results from the Ongoing Phase 3 BRIGHT51 Open-label Extension Study,” Poster Presentation By John Bernat, M.D., Ph.D.	“Long-term Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: 2-year Interim Results from the Ongoing Phase 3 BRIGHT51 Open-label Extension Study,” Poster Presentation By John Bernat, M.D., Ph.D. 1.1 MB
12/05/22	KOL Event Presentation – Myrl D. Holida, PA-C	KOL Event Presentation – Myrl D. Holida, PA-C 2.9 MB
05/29/22	Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease - 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-label Study; Abstract from the 7th Update on Fabry Disease	Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease - 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-label Study; Abstract from the 7th Update on Fabry Disease 46.6 KB
05/29/22	Long-term Safety and Efficacy of Pegunigalsidase Alfa - A Multicenter Extension Study in Adult Patients with Fabry Disease; Poster from the 7th Update on Fabry Disease	Long-term Safety and Efficacy of Pegunigalsidase Alfa - A Multicenter Extension Study in Adult Patients with Fabry Disease; Poster from the 7th Update on Fabry Disease 1.8 MB
05/29/22	Long-term Safety and Efficacy of Pegunigalsidase Alfa - A Multicenter Extension Study in Adult Patients with Fabry Disease; Abstract from the 7th Update on Fabry Disease	Long-term Safety and Efficacy of Pegunigalsidase Alfa - A Multicenter Extension Study in Adult Patients with Fabry Disease; Abstract from the 7th Update on Fabry Disease 59.5 KB
05/29/22	Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients With Fabry Disease - Data From 5 Completed Clinical Trials; Abstract from the 7th Update on Fabry Disease	Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients With Fabry Disease - Data From 5 Completed Clinical Trials; Abstract from the 7th Update on Fabry Disease 61.4 KB
05/29/22	Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease - 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-Label Study; Poster from the 7th Update on Fabry Disease	Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease - 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-Label Study; Poster from the 7th Update on Fabry Disease 20.9 MB
05/29/22	Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease - Results from the Phase 3, Open-Label, BRIGHT Study; Poster from the 7th Update on Fabry Disease	Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease - Results from the Phase 3, Open-Label, BRIGHT Study; Poster from the 7th Update on Fabry Disease 3.9 MB
05/29/22	Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease - Results from the Phase 3, Open-label, BRIGHT Study; Abstract from the 7th Update on Fabry Disease	Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease - Results from the Phase 3, Open-label, BRIGHT Study; Abstract from the 7th Update on Fabry Disease 67.3 KB
05/29/22	Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients with Fabry Disease - Data from 5 Completed Clinical Trials; Poster from the 7th Update on Fabry Disease	Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients with Fabry Disease - Data from 5 Completed Clinical Trials; Poster from the 7th Update on Fabry Disease 456.8 KB

Presentations

Presentations

PRESENTATIONS